John Ucci
Family Medicine · Chillicothe, OHNPI 1194718049
Payments from drug & device makers
Across 109 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$588
- Pfizer$289
- Alkermes, Inc.$248
- AstraZeneca$182
- Bayer$138
- Phathom Pharmaceuticals, Inc.$76
- plus $500 from 13 others
What the payments were for
- Food & beverage$2,022100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $588 |
| Pfizer | 15 | $289 |
| Alkermes, Inc. | 11 | $248 |
| AstraZeneca | 6 | $182 |
| Bayer | 8 | $138 |
| Phathom Pharmaceuticals, Inc. | 4 | $76 |
| GSK | 4 | $74 |
| Novo Nordisk | 4 | $66 |
| Boehringer Ingelheim | 3 | $63 |
| Abbott | 3 | $57 |
| Xeris Pharmaceuticals, Inc. | 2 | $48 |
| Exact Sciences | 2 | $38 |
| Hologic Sales And Service, LLC | 2 | $31 |
| Merck | 2 | $29 |
| Dexcom, Inc. | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
How this compares
$2,022 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 97 | $123,393 |
| EliquisApixaban | 95 | $61,055 |
| TradjentaLinagliptin | 43 | $52,038 |
| JanuviaSitagliptin Phosphate | 35 | $49,710 |
| XareltoRivaroxaban | 32 | $33,920 |
| Spiriva RespimatTiotropium Bromide | 42 | $32,383 |
| TrulicityDulaglutide | 26 | $30,718 |
| FarxigaDapagliflozin Propanediol | 12 | $18,743 |
| OzempicSemaglutide | 14 | $18,016 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $13,489 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $12,705 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $12,408 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $9,161 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 220 | $8,342 |
| LinzessLinaclotide | 11 | $6,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $63 | $207,814182 claims |
| PfizerEliquis | $289 | $61,05595 claims |
| MerckJanuvia, Dulera | $29 | $55,29147 claims |
| AstraZenecaFarxiga, Symbicort | $182 | $32,23244 claims |
| Lilly USA, LLCTrulicity | $16 | $30,71826 claims |
| GSKIncruse Ellipta, Breo Ellipta, Anoro Ellipta | $74 | $30,15262 claims |
| Novo NordiskOzempic | $66 | $18,01614 claims |
| AbbVieLinzess | $588 | $6,78611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Chillicothe
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.